Vitamin D for COVID-19 Trial

Summary

The Vitamin D for COVID-19 Trial (VIVID) is a randomized, placebo-controlled clinical trial in 2024 men and women from across the U.S. and Mongolia to investigate whether taking a daily dietary supplement of vitamin D vs. placebo for 4 weeks reduces the rate of seeking healthcare for symptoms or concerns related to COVID-19 in participants recently diagnosed with COVID-19, and reduces the risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in household contacts of individuals with newly diagnosed COVID-19.

Conditions

• COVID-19

Interventions

DIETARY_SUPPLEMENT

vitamin D

Vitamin D softgel capsules; each capsule contains 3200 IU of vitamin D3. Three capsules per day (9600 IU/day) will be taken on days 1 and 2, and one capsule per day (3200 IU/day) will be taken on days 3 through 28

DIETARY_SUPPLEMENT

Placebo

Placebo softgel capsules. Three capsules per day will be taken on days 1 and 2, and one capsule per day will be taken on days 3 through 28

Sponsors & Collaborators

• Harvard Medical School (HMS and HSDM)

  collaborator OTHER

• Harvard School of Public Health (HSPH)

  collaborator OTHER

• Fenway Health and Beth Israel Deaconess Medical Center

  collaborator UNKNOWN

• Tishcon Corporation

  collaborator UNKNOWN

• Takeda

  collaborator INDUSTRY

• Quest Diagnostics-Nichols Insitute

  collaborator INDUSTRY

• Laboratory Corporation of America

  collaborator INDUSTRY

• Trialfacts

  collaborator UNKNOWN

• Karolinska Institutet

  collaborator OTHER

• Philanthropic donations

  collaborator UNKNOWN

• Brigham and Women's Hospital

  lead OTHER

Principal Investigators

• JoAnn E Manson, MD, DrPH · Brigham and Women's Hospital

• Rui Wang, PhD · Harvard Medical School (HMS and HSDM)

• Davaasambuu Ganmaa, PhD · Harvard School of Public Health (HSPH)

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2020-12-28

Primary Completion

2024-07-01

Completion

2024-07-01

Countries

• United States

Study Locations